Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition
AuthorsPaliouras, Athanasios R
Leong, Hui Sun
Di Leva, G
Krebs, Matthew G
Blackhall, Fiona H
AffiliationTranscriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractA subset of lung adenocarcinomas is driven by the EML4-ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on-target mutations or parallel pathway alterations is a major clinical challenge. Exploring these mechanisms of resistance, we found that EML4-ALK cells parental or resistant to crizotinib, ceritinib or alectinib are remarkably sensitive to inhibition of CDK7/12 with THZ1 and CDK9 with alvocidib or dinaciclib. These compounds robustly induce apoptosis through transcriptional inhibition and downregulation of anti-apoptotic genes. Importantly, alvocidib reduced tumour progression in xenograft mouse models. In summary, our study takes advantage of the transcriptional addiction hypothesis to propose a new treatment strategy for a subset of patients with acquired resistance to first-, second- and third-generation ALK inhibitors. Keywords: ALK/EML4 translocation; ALKi; CDKi; NSCLC; drug resistance.
CitationPaliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, et al. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. EMBO Mol Med. 2020;12(7):e11099.
JournalEMBO Molecular Medicine
- Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
- Authors: Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K
- Issue date: 2016 Nov
- Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
- Authors: Oh SJ, Noh KH, Lee YH, Hong SO, Song KH, Lee HJ, Kim S, Kim TM, Jeon JH, Seo JH, Kim DW, Kim TW
- Issue date: 2015 Nov 24
- Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
- Authors: Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K
- Issue date: 2016 Mar 15
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
- Authors: Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N
- Issue date: 2016 Jan
- Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review.
- Authors: Kougioumtzi A, Ntellas P, Papadopoulou E, Nasioulas G, Kampletsas E, Pentheroudakis G
- Issue date: 2019